eRAM

encyclopedia of Rare Disease Annotation for Precision Medicine

HOME
QUERY
- DISEASE
- GENOTYPE
NETWORK
- PHENOTYPE
- GENE
- COMMON
- DISEASE PAIR
DOWNLOAD
SUBMIT CASE
HELP&FAQ
- HELP&FAQ
- CONTACT US


	diffuse large b-cell lymphoma

Disease ID	622
Disease	diffuse large b-cell lymphoma
Definition	Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.
Synonym	[m]malignant lymphoma, large cell, diffuse nos diffuse histiocytic lymphoma diffuse histiocytic lymphomas diffuse large b cell lymphoma diffuse large cell lymphoma diffuse large lymphoma diffuse large-cell lymphoma diffuse large-cell lymphomas diffuse malignant lymphoma - histiocytic diffuse malignant lymphoma - large cell diffuse non-hodgkin lymphoma, large cell diffuse non-hodgkin's lymphoma, large cell diffuse non-hodgkin's lymphoma, large cell (clinical) diffuse non-hodgkin's lymphoma, large cell (disorder) diffuse, large b-cell, lymphoma dlbcl histiocytic lymphoma, diffuse histiocytic lymphomas histiocytic lymphomas, diffuse large cell diffuse lymphoma large cell lymphoma, diffuse large lymphoid lymphoma, diffuse large lymphoma diffuse large-cell lymphoma, diffuse large-cell lymphomas, diffuse lymphoma diffuse large lymphoma large diffuse lymphoma, diffuse histiocytic lymphoma, diffuse large b cell, non hodgkins lymphoma, diffuse large cell lymphoma, diffuse large-cell lymphoma, histiocytic lymphoma, histiocytic, diffuse lymphoma, large b-cell, diffuse lymphoma, large b-cell, diffuse [disease/finding] lymphoma, large cell, diffuse lymphoma, large lymphoid, diffuse lymphoma, large-cell, diffuse lymphomas, diffuse histiocytic lymphomas, diffuse large-cell lymphomas, histiocytic malignant lymphoma - large cell cleaved and non-cleaved malignant lymphoma, histiocytic malignant lymphoma, histiocytic, diffuse malignant lymphoma, histiocytic, nos malignant lymphoma, large b-cell malignant lymphoma, large b-cell, diffuse malignant lymphoma, large b-cell, diffuse (morphologic abnormality) malignant lymphoma, large b-cell, diffuse, no icd-o subtype malignant lymphoma, large b-cell, diffuse, no icd-o subtype (morphologic abnormality) malignant lymphoma, large b-cell, diffuse, no international classification of diseases for oncology subtype malignant lymphoma, large b-cell, diffuse, no international classification of diseases for oncology subtype (morphologic abnormality) malignant lymphoma, large cell malignant lymphoma, large cell, cleaved and noncleaved malignant lymphoma, large cell, diffuse [obs] malignant lymphoma, large cell, diffuse, nos malignant lymphoma, large cell, nos
Orphanet	ORPHANET:544
DOID	DOID:0050745
UMLS	C0079744
MeSH	D016403
SNOMED-CT	SNOMEDCT_US_2016_09_01:109969005
Comorbidity	UMLS \| Disease \| Sentences' Count(Total Sentences:117) C0024299 \| lymphoma \| 26 C0079731 \| b-cell lymphoma \| 11 C0024299 \| lymphomas \| 10 C0042769 \| virus infection \| 7 C0019196 \| hepatitis c \| 6 C0019158 \| hepatitis \| 6 C0024301 \| follicular lymphoma \| 6 C0023434 \| chronic lymphocytic leukemia \| 4 C0079731 \| b-cell lymphomas \| 4 C0019163 \| hepatitis b \| 4 C0024305 \| non-hodgkin's lymphoma \| 3 C0079744 \| diffuse large b-cell lymphoma \| 3 C0032285 \| pneumonia \| 3 C0024291 \| hemophagocytic syndrome \| 3 C0019829 \| hodgkin's lymphoma \| 3 C0030807 \| pemphigus \| 3 C0001430 \| adenoma \| 2 C0019360 \| zoster \| 2 C0242647 \| mucosa-associated lymphoid tissue \| 2 C0022398 \| hyper-ige syndrome \| 2 C0349644 \| testicular lymphoma \| 2 C0278701 \| gastric adenocarcinoma \| 2 C0030489 \| paraproteinemia \| 2 C0032305 \| pneumocystis \| 2 C0023418 \| leukemia \| 2 C0032305 \| pneumocystis jiroveci pneumonia \| 2 C0001125 \| lactic acidosis \| 2 C0002878 \| hemolytic anemia \| 2 C0023448 \| lymphocytic leukemia \| 2 C0002880 \| autoimmune hemolytic anemia \| 2 C1527336 \| sjogren's syndrome \| 2 C0002871 \| anemia \| 2 C0018799 \| heart disease \| 1 C0022660 \| acute renal failure \| 1 C0024314 \| lymphoproliferative disorder \| 1 C0041327 \| pulmonary tuberculosis \| 1 C0019829 \| hodgkin lymphoma \| 1 C0004134 \| ataxia \| 1 C0027022 \| myeloproliferative disorder \| 1 C0024141 \| systemic lupus erythematosus \| 1 C0032285 \| pneumonitis \| 1 C0023448 \| lymphocytic leukaemia \| 1 C0020676 \| hypothyroidism \| 1 C0242647 \| malt lymphoma \| 1 C0023418 \| leukaemia \| 1 C0021843 \| intestinal obstruction \| 1 C0032000 \| pituitary adenoma \| 1 C0004135 \| ataxia telangiectasia \| 1 C0015464 \| facial nerve palsy \| 1 C0206083 \| central pontine myelinolysis \| 1 C0349631 \| richter's syndrome \| 1 C0206702 \| klatskin tumor \| 1 C0079731 \| b cell lymphoma \| 1 C0003873 \| rheumatoid arthritis \| 1 C0085404 \| poems syndrome \| 1 C0001418 \| adenocarcinoma \| 1 C0031039 \| pericardial effusion \| 1 C0009324 \| ulcerative colitis \| 1 C1565489 \| renal insufficiency \| 1 C0024302 \| large cell lymphoma \| 1 C1368903 \| cystic teratoma \| 1 C0039446 \| telangiectasia \| 1 C0272286 \| immune thrombocytopenia \| 1 C0409974 \| lupus erythematosus \| 1 C0549473 \| thyroid carcinoma \| 1 C0042384 \| vasculitis \| 1 C0024299 \| malignant lymphoma \| 1 C0024301 \| follicular lymphomas \| 1 C0039538 \| teratoma \| 1 C0151436 \| leukocytoclastic vasculitis \| 1 C0002726 \| amyloidosis \| 1 C0028756 \| severe obesity \| 1 C0020437 \| hypercalcaemia \| 1 C0035435 \| rheumatic disease \| 1 C0238463 \| papillary thyroid carcinoma \| 1 C0023434 \| chronic lymphocytic leukaemia \| 1 C0028754 \| obesity \| 1 C0037753 \| sparganosis \| 1 C0041296 \| tuberculosis \| 1 C0238198 \| gastrointestinal stromal tumor \| 1 C0003864 \| arthritis \| 1 C0751931 \| femoral nerve palsy \| 1 C0020635 \| hypopituitarism \| 1 C0242584 \| autoimmune thrombocytopenia \| 1 C0011570 \| depression \| 1 C0024419 \| waldenstrom's macroglobulinemia \| 1 C0679362 \| extrapulmonary tuberculosis \| 1 C0079731 \| b-cell non-hodgkin's lymphoma \| 1 C0007115 \| thyroid ca \| 1 C2700641 \| lymphoplasmacytic lymphoma \| 1 C0029443 \| osteomyelitis \| 1 C0019112 \| hemorrhoids \| 1 C0879615 \| stromal tumor \| 1 C0035222 \| acute respiratory distress syndrome \| 1 C0011649 \| mature cystic teratoma \| 1 C0019360 \| herpes zoster \| 1 C0001623 \| adrenal insufficiency \| 1 C0020437 \| hypercalcemia \| 1 C0238114 \| esophageal leiomyoma \| 1 C0027809 \| schwannoma \| 1 C0040034 \| thrombocytopenia \| 1 C0021053 \| immune disease \| 1 C0043194 \| wiskott-aldrich syndrome \| 1 C0031046 \| pericarditis \| 1 C0334634 \| mantle cell lymphoma \| 1 C0024796 \| marfan syndrome \| 1 C1704437 \| respiratory distress syndrome \| 1 C0024305 \| non-hodgkin lymphoma \| 1 C0035078 \| renal failure \| 1 C0022354 \| obstructive jaundice \| 1 C0027059 \| myocarditis \| 1 C0024115 \| lung disease \| 1 C0036202 \| sarcoidosis \| 1 C0206180 \| anaplastic large cell lymphoma \| 1 C0206062 \| interstitial lung disease \| 1 C0376545 \| hematologic malignancies \| 1 C0011849 \| diabetes mellitus \| 1
Curated Gene	Entrez_id \| Symbol \| Resource(Total Genes:38) 3106 \| HLA-B \| GWASCAT 5243 \| ABCB1 \| CTD_human 4615 \| MYD88 \| CTD_human 9429 \| ABCG2 \| CTD_human 596 \| BCL2 \| CTD_human 1029 \| CDKN2A \| CTD_human 6648 \| SOD2 \| CTD_human 10892 \| MALT1 \| CTD_human 847 \| CAT \| CTD_human 567 \| B2M \| CTD_human 8085 \| KMT2D \| CTD_human 5290 \| PIK3CA \| CTD_human 10628 \| TXNIP \| CTD_human 238 \| ALK \| CTD_human 10935 \| PRDX3 \| CTD_human 10549 \| PRDX4 \| CTD_human 84433 \| CARD11 \| CTD_human 355 \| FAS \| CTD_human 983 \| CDK1 \| CTD_human 79080 \| CCDC86 \| CTD_human 64434 \| NOM1 \| CTD_human 5820 \| PVT1 \| GWASCAT 2146 \| EZH2 \| CTD_human 942 \| CD86 \| GWASCAT 5293 \| PIK3CD \| CTD_human 5294 \| PIK3CG \| CTD_human 5291 \| PIK3CB \| CTD_human 5170 \| PDPK1 \| CTD_human 6502 \| SKP2 \| CTD_human 2735 \| GLI1 \| CTD_human 1213 \| CLTC \| CTD_human 6198 \| RPS6KB1 \| CTD_human 64411 \| ARAP3 \| GWASCAT 6649 \| SOD3 \| CTD_human 974 \| CD79B \| CTD_human 973 \| CD79A \| CTD_human 22872 \| SEC31A \| CTD_human 102465537 \| MIR6891 \| GWASCAT
Inferring Gene	Entrez_id \| Symbol \| Resource(Total Genes:88) 472 \| ATM \| CIPHER 4609 \| MYC \| CIPHER 596 \| BCL2 \| CIPHER;CTD_human 729230 \| CCR2 \| CIPHER 1234 \| CCR5 \| CIPHER 9578 \| CDC42BPB \| CIPHER 1440 \| CSF3 \| CIPHER 1493 \| CTLA4 \| CIPHER 1524 \| CX3CR1 \| CIPHER 6387 \| CXCL12 \| CIPHER 1543 \| CYP1A1 \| CIPHER 2212 \| FCGR2A \| CIPHER 2950 \| GSTP1 \| CIPHER 2952 \| GSTT1 \| CIPHER 3383 \| ICAM1 \| CIPHER 3439 \| IFNA1 \| CIPHER 3458 \| IFNG \| CIPHER 3459 \| IFNGR1 \| CIPHER 3460 \| IFNGR2 \| CIPHER 3586 \| IL10 \| CIPHER 3587 \| IL10RA \| CIPHER 3592 \| IL12A \| CIPHER 3593 \| IL12B \| CIPHER 3596 \| IL13 \| CIPHER 3600 \| IL15 \| CIPHER 3601 \| IL15RA \| CIPHER 3603 \| IL16 \| CIPHER 3552 \| IL1A \| CIPHER 3553 \| IL1B \| CIPHER 3557 \| IL1RN \| CIPHER 3558 \| IL2 \| CIPHER 3562 \| IL3 \| CIPHER 3565 \| IL4 \| CIPHER 3566 \| IL4R \| CIPHER 3567 \| IL5 \| CIPHER 3569 \| IL6 \| CIPHER 3575 \| IL7R \| CIPHER 3578 \| IL9 \| CIPHER 3581 \| IL9R \| CIPHER 3718 \| JAK3 \| CIPHER 4049 \| LTA \| CIPHER 4153 \| MBL2 \| CIPHER 4193 \| MDM2 \| CIPHER 931 \| MS4A1 \| CIPHER 4524 \| MTHFR \| CIPHER 64127 \| NOD2 \| CIPHER 1728 \| NQO1 \| CIPHER 51082 \| POLR1D \| CIPHER 6401 \| SELE \| CIPHER 6772 \| STAT1 \| CIPHER 7099 \| TLR4 \| CIPHER 7124 \| TNF \| CIPHER 8797 \| TNFRSF10A \| CIPHER 7157 \| TP53 \| CIPHER 7412 \| VCAM1 \| CIPHER 7515 \| XRCC1 \| CIPHER 9429 \| ABCG2 \| CTD_human 10892 \| MALT1 \| CTD_human 10628 \| TXNIP \| CTD_human 10935 \| PRDX3 \| CTD_human 10549 \| PRDX4 \| CTD_human 983 \| CDK1 \| CTD_human 79080 \| CCDC86 \| CTD_human 64434 \| NOM1 \| CTD_human 355 \| FAS \| CTD_human 5293 \| PIK3CD \| CTD_human 5294 \| PIK3CG \| CTD_human 5290 \| PIK3CA \| CTD_human 5291 \| PIK3CB \| CTD_human 5170 \| PDPK1 \| CTD_human 6502 \| SKP2 \| CTD_human 847 \| CAT \| CTD_human 238 \| ALK \| CTD_human 6648 \| SOD2 \| CTD_human 84433 \| CARD11 \| CTD_human 2735 \| GLI1 \| CTD_human 1213 \| CLTC \| CTD_human 5243 \| ABCB1 \| CTD_human 567 \| B2M \| CTD_human 6198 \| RPS6KB1 \| CTD_human 2146 \| EZH2 \| CTD_human 974 \| CD79B \| CTD_human 973 \| CD79A \| CTD_human 22872 \| SEC31A \| CTD_human 1029 \| CDKN2A \| CTD_human 8085 \| KMT2D \| CTD_human 4615 \| MYD88 \| CTD_human 6649 \| SOD3 \| CTD_human
Text Mined Gene	Entrez_id \| Symbol \| Score \| Resource(Total Genes:253) 27 \| ABL2 \| 1.305 \| DISEASES 197322 \| ACSF3 \| 1.529 \| DISEASES 238 \| ALK \| 4.19 \| DISEASES 83478 \| ARHGAP24 \| 1.103 \| DISEASES 8289 \| ARID1A \| 1.495 \| DISEASES 79754 \| ASB13 \| 2.654 \| DISEASES 22809 \| ATF5 \| 1.409 \| DISEASES 567 \| B2M \| 3.423 \| DISEASES 9564 \| BCAR1 \| 1.197 \| DISEASES 10286 \| BCAS2 \| 1.434 \| DISEASES 53335 \| BCL11A \| 2.224 \| DISEASES 10018 \| BCL2L11 \| 2.244 \| DISEASES 605 \| BCL7A \| 2.62 \| DISEASES 54880 \| BCOR \| 1.279 \| DISEASES 112401 \| BIRC8 \| 1.32 \| DISEASES 9790 \| BMS1 \| 1.958 \| DISEASES 6046 \| BRD2 \| 1.84 \| DISEASES 712 \| C1QA \| 1.354 \| DISEASES 23705 \| CADM1 \| 2.064 \| DISEASES 84433 \| CARD11 \| 5.433 \| DISEASES 152137 \| CCDC50 \| 1.378 \| DISEASES 896 \| CCND3 \| 3.487 \| DISEASES 1237 \| CCR8 \| 1.532 \| DISEASES 10803 \| CCR9 \| 1.416 \| DISEASES 10693 \| CCT6B \| 2.05 \| DISEASES 9332 \| CD163 \| 2.389 \| DISEASES 930 \| CD19 \| 4.424 \| DISEASES 914 \| CD2 \| 2.346 \| DISEASES 4345 \| CD200 \| 1.773 \| DISEASES 29126 \| CD274 \| 2.948 \| DISEASES 11314 \| CD300A \| 2.15 \| DISEASES 951 \| CD37 \| 1.593 \| DISEASES 958 \| CD40 \| 2.838 \| DISEASES 959 \| CD40LG \| 2.565 \| DISEASES 960 \| CD44 \| 2.143 \| DISEASES 921 \| CD5 \| 5.724 \| DISEASES 1043 \| CD52 \| 1.446 \| DISEASES 965 \| CD58 \| 2.147 \| DISEASES 974 \| CD79B \| 4.564 \| DISEASES 926 \| CD8B \| 4.098 \| DISEASES 9578 \| CDC42BPB \| 1.588 \| DISEASES 1029 \| CDKN2A \| 3.201 \| DISEASES 1147 \| CHUK \| 1.212 \| DISEASES 1378 \| CR1 \| 1.694 \| DISEASES 1380 \| CR2 \| 3.44 \| DISEASES 158511 \| CSAG1 \| 1.994 \| DISEASES 10675 \| CSPG5 \| 1.883 \| DISEASES 7852 \| CXCR4 \| 1.969 \| DISEASES 1612 \| DAPK1 \| 2.817 \| DISEASES 81623 \| DEFB126 \| 1.489 \| DISEASES 8449 \| DHX16 \| 1.082 \| DISEASES 56616 \| DIABLO \| 1.255 \| DISEASES 1791 \| DNTT \| 2.328 \| DISEASES 113878 \| DTX2 \| 1.698 \| DISEASES 196403 \| DTX3 \| 1.949 \| DISEASES 1847 \| DUSP5 \| 2.042 \| DISEASES 1850 \| DUSP8 \| 1.373 \| DISEASES 10209 \| EIF1 \| 1.028 \| DISEASES 1974 \| EIF4A2 \| 1.273 \| DISEASES 1977 \| EIF4E \| 1.349 \| DISEASES 317649 \| EIF4E3 \| 1.373 \| DISEASES 1978 \| EIF4EBP1 \| 1.552 \| DISEASES 1981 \| EIF4G1 \| 1.39 \| DISEASES 8672 \| EIF4G3 \| 1.897 \| DISEASES 3266 \| ERAS \| 1.17 \| DISEASES 2159 \| F10 \| 1.629 \| DISEASES 2173 \| FABP7 \| 1.135 \| DISEASES 23116 \| FAM179B \| 1.823 \| DISEASES 355 \| FAS \| 1.879 \| DISEASES 2214 \| FCGR3A \| 1.973 \| DISEASES 2272 \| FHIT \| 1.67 \| DISEASES 2335 \| FN1 \| 2.261 \| DISEASES 50943 \| FOXP3 \| 2.293 \| DISEASES 6624 \| FSCN1 \| 1.866 \| DISEASES 8880 \| FUBP1 \| 1.578 \| DISEASES 2526 \| FUT4 \| 3.606 \| DISEASES 53827 \| FXYD5 \| 1.504 \| DISEASES 2564 \| GABRE \| 1.857 \| DISEASES 79695 \| GALNT12 \| 1.384 \| DISEASES 257144 \| GCSAM \| 4.083 \| DISEASES 10672 \| GNA13 \| 4.325 \| DISEASES 2782 \| GNB1 \| 1.077 \| DISEASES 51125 \| GOLGA7 \| 1.835 \| DISEASES 2857 \| GPR34 \| 1.439 \| DISEASES 2873 \| GPS1 \| 1.624 \| DISEASES 2885 \| GRB2 \| 1.039 \| DISEASES 2950 \| GSTP1 \| 1.497 \| DISEASES 3065 \| HDAC1 \| 1.507 \| DISEASES 3066 \| HDAC2 \| 1.032 \| DISEASES 10013 \| HDAC6 \| 1.571 \| DISEASES 3010 \| HIST1H1T \| 1.469 \| DISEASES 3122 \| HLA-DRA \| 1.596 \| DISEASES 388697 \| HRNR \| 1.927 \| DISEASES 219844 \| HYLS1 \| 3.018 \| DISEASES 23308 \| ICOSLG \| 1.325 \| DISEASES 3399 \| ID3 \| 1.812 \| DISEASES 10437 \| IFI30 \| 1.534 \| DISEASES 100423062 \| IGLL5 \| 2.664 \| DISEASES 3551 \| IKBKB \| 1.588 \| DISEASES 8517 \| IKBKG \| 1.486 \| DISEASES 10320 \| IKZF1 \| 1.556 \| DISEASES 22806 \| IKZF3 \| 1.613 \| DISEASES 3586 \| IL10 \| 3.096 \| DISEASES 50615 \| IL21R \| 1.216 \| DISEASES 3559 \| IL2RA \| 1.147 \| DISEASES 3635 \| INPP5D \| 2.043 \| DISEASES 3662 \| IRF4 \| 5.345 \| DISEASES 3709 \| ITPR2 \| 1.99 \| DISEASES 3710 \| ITPR3 \| 1.41 \| DISEASES 3713 \| IVL \| 2.876 \| DISEASES 3717 \| JAK2 \| 2.05 \| DISEASES 3725 \| JUN \| 1.453 \| DISEASES 3767 \| KCNJ11 \| 1.896 \| DISEASES 56660 \| KCNK12 \| 1.468 \| DISEASES 2531 \| KDSR \| 1.638 \| DISEASES 3796 \| KIF2A \| 1.142 \| DISEASES 57565 \| KLHL14 \| 2.18 \| DISEASES 89857 \| KLHL6 \| 2.445 \| DISEASES 55975 \| KLHL7 \| 1.868 \| DISEASES 3981 \| LIG4 \| 1.218 \| DISEASES 9516 \| LITAF \| 1.234 \| DISEASES 222484 \| LNX2 \| 1.553 \| DISEASES 9361 \| LONP1 \| 1.077 \| DISEASES 4033 \| LRMP \| 2.553 \| DISEASES 104564224 \| LUNAR1 \| 2.365 \| DISEASES 4067 \| LYN \| 1.608 \| DISEASES 10905 \| MAN1A2 \| 1.932 \| DISEASES 5600 \| MAPK11 \| 1.147 \| DISEASES 5599 \| MAPK8 \| 1.073 \| DISEASES 4170 \| MCL1 \| 3.056 \| DISEASES 4193 \| MDM2 \| 1.789 \| DISEASES 114614 \| MIR155HG \| 1.696 \| DISEASES 407975 \| MIR17HG \| 3.071 \| DISEASES 4311 \| MME \| 6.256 \| DISEASES 4332 \| MNDA \| 2.515 \| DISEASES 79710 \| MORC4 \| 1.719 \| DISEASES 9242 \| MSC \| 1.612 \| DISEASES 4524 \| MTHFR \| 1.539 \| DISEASES 2475 \| MTOR \| 2.572 \| DISEASES 84939 \| MUM1 \| 2.654 \| DISEASES 4603 \| MYBL1 \| 2.826 \| DISEASES 4609 \| MYC \| 6.034 \| DISEASES 4615 \| MYD88 \| 4.543 \| DISEASES 4689 \| NCF4 \| 1.14 \| DISEASES 4751 \| NEK2 \| 1.626 \| DISEASES 4791 \| NFKB2 \| 2.17 \| DISEASES 64332 \| NFKBIZ \| 1.943 \| DISEASES 10360 \| NPM3 \| 1.356 \| DISEASES 8650 \| NUMB \| 1.231 \| DISEASES 114884 \| OSBPL10 \| 1.437 \| DISEASES 286530 \| P2RY8 \| 1.672 \| DISEASES 142 \| PARP1 \| 1.217 \| DISEASES 54625 \| PARP14 \| 2.802 \| DISEASES 165631 \| PARP15 \| 1.37 \| DISEASES 83666 \| PARP9 \| 3.032 \| DISEASES 139135 \| PASD1 \| 3.124 \| DISEASES 5079 \| PAX5 \| 5.103 \| DISEASES 7849 \| PAX8 \| 1.235 \| DISEASES 5133 \| PDCD1 \| 2.251 \| DISEASES 80380 \| PDCD1LG2 \| 2.976 \| DISEASES 5142 \| PDE4B \| 2.596 \| DISEASES 9260 \| PDLIM7 \| 3.221 \| DISEASES 57162 \| PELI1 \| 1.244 \| DISEASES 8301 \| PICALM \| 1.706 \| DISEASES 5292 \| PIM1 \| 2.113 \| DISEASES 11040 \| PIM2 \| 2.632 \| DISEASES 5336 \| PLCG2 \| 1.987 \| DISEASES 5406 \| PNLIP \| 2.446 \| DISEASES 5450 \| POU2AF1 \| 3.249 \| DISEASES 5452 \| POU2F2 \| 2.859 \| DISEASES 5529 \| PPP2R5E \| 1.31 \| DISEASES 5530 \| PPP3CA \| 1.355 \| DISEASES 23532 \| PRAME \| 1.294 \| DISEASES 639 \| PRDM1 \| 4.662 \| DISEASES 59336 \| PRDM13 \| 1.903 \| DISEASES 5728 \| PTEN \| 2.279 \| DISEASES 5744 \| PTHLH \| 1.31 \| DISEASES 5783 \| PTPN13 \| 1.654 \| DISEASES 5777 \| PTPN6 \| 1.684 \| DISEASES 5788 \| PTPRC \| 3.817 \| DISEASES 5795 \| PTPRJ \| 1.728 \| DISEASES 5820 \| PVT1 \| 1.508 \| DISEASES 5872 \| RAB13 \| 1.099 \| DISEASES 5887 \| RAD23B \| 1.01 \| DISEASES 5905 \| RANGAP1 \| 1.796 \| DISEASES 221002 \| RASGEF1A \| 1.499 \| DISEASES 166824 \| RASSF6 \| 1.047 \| DISEASES 10616 \| RBCK1 \| 1.505 \| DISEASES 9939 \| RBM8A \| 1.275 \| DISEASES 5991 \| RFX3 \| 1.239 \| DISEASES 6003 \| RGS13 \| 1.529 \| DISEASES 64407 \| RGS18 \| 1.054 \| DISEASES 399 \| RHOH \| 3.764 \| DISEASES 253260 \| RICTOR \| 1.807 \| DISEASES 54101 \| RIPK4 \| 1.718 \| DISEASES 6194 \| RPS6 \| 1.014 \| DISEASES 64121 \| RRAGC \| 1.373 \| DISEASES 84816 \| RTN4IP1 \| 1.31 \| DISEASES 9294 \| S1PR2 \| 2.516 \| DISEASES 27164 \| SALL3 \| 1.298 \| DISEASES 677681 \| SCARNA20 \| 2.601 \| DISEASES 23231 \| SEL1L3 \| 1.916 \| DISEASES 327657 \| SERPINA9 \| 4.679 \| DISEASES 9467 \| SH3BP5 \| 1.688 \| DISEASES 81858 \| SHARPIN \| 1.097 \| DISEASES 144195 \| SLC2A14 \| 1.576 \| DISEASES 347734 \| SLC35B2 \| 3.845 \| DISEASES 83650 \| SLC35G5 \| 1.569 \| DISEASES 4090 \| SMAD5 \| 1.019 \| DISEASES 6597 \| SMARCA4 \| 1.103 \| DISEASES 23583 \| SMUG1 \| 5.093 \| DISEASES 6622 \| SNCA \| 3.314 \| DISEASES 387066 \| SNHG5 \| 1.445 \| DISEASES 9304 \| SNORD22 \| 1.329 \| DISEASES 692225 \| SNORD94 \| 1.33 \| DISEASES 6643 \| SNX2 \| 1.424 \| DISEASES 8651 \| SOCS1 \| 2.005 \| DISEASES 9021 \| SOCS3 \| 1.013 \| DISEASES 22986 \| SORCS3 \| 1.272 \| DISEASES 6664 \| SOX11 \| 2.977 \| DISEASES 23013 \| SPEN \| 2.345 \| DISEASES 23111 \| SPG20 \| 1.261 \| DISEASES 6689 \| SPIB \| 2.74 \| DISEASES 6693 \| SPN \| 3.823 \| DISEASES 6772 \| STAT1 \| 1.444 \| DISEASES 56241 \| SUSD2 \| 1.121 \| DISEASES 22987 \| SV2C \| 1.015 \| DISEASES 6850 \| SYK \| 3.294 \| DISEASES 23345 \| SYNE1 \| 1.459 \| DISEASES 6861 \| SYT5 \| 1.737 \| DISEASES 79718 \| TBL1XR1 \| 2.118 \| DISEASES 7062 \| TCHH \| 1.177 \| DISEASES 8115 \| TCL1A \| 2.383 \| DISEASES 54790 \| TET2 \| 1.04 \| DISEASES 7072 \| TIA1 \| 2.537 \| DISEASES 7088 \| TLE1 \| 1.036 \| DISEASES 54106 \| TLR9 \| 1.072 \| DISEASES 55116 \| TMEM39B \| 2.654 \| DISEASES 7124 \| TNF \| 2.239 \| DISEASES 25816 \| TNFAIP8 \| 1.529 \| DISEASES 8764 \| TNFRSF14 \| 1.992 \| DISEASES 3604 \| TNFRSF9 \| 1.431 \| DISEASES 10673 \| TNFSF13B \| 2.849 \| DISEASES 79155 \| TNIP2 \| 1.146 \| DISEASES 23112 \| TNRC6B \| 1.344 \| DISEASES 27010 \| TPK1 \| 1.148 \| DISEASES 7185 \| TRAF1 \| 2.228 \| DISEASES 7422 \| VEGFA \| 1.733 \| DISEASES 331 \| XIAP \| 2.41 \| DISEASES 7514 \| XPO1 \| 1.896 \| DISEASES 4904 \| YBX1 \| 1.384 \| DISEASES 340152 \| ZC3H12D \| 4.848 \| DISEASES 79683 \| ZDHHC14 \| 1.407 \| DISEASES
Locus	(Waiting for update.)

Disease ID	622
Disease	diffuse large b-cell lymphoma
Integrated Phenotype	(Waiting for update.)
Text Mined Phenotype	HPO \| Name \| Sentences' Count(Total Phenotypes:73) HP:0002665 \| Lymphoma \| 27 HP:0002664 \| Neoplasia \| 27 HP:0012191 \| B-cell lymphoma \| 13 HP:0012115 \| Liver inflammation \| 6 HP:0000718 \| Aggressive behaviour \| 4 HP:0012189 \| Hodgkin disease \| 4 HP:0005550 \| Chronic lymphatic leukemia \| 4 HP:0002716 \| Lymph node hyperplasia \| 3 HP:0002090 \| Pneumonia \| 3 HP:0001878 \| Haemolytic anaemia \| 2 HP:0001890 \| Autoimmune hemolytic anemia \| 2 HP:0012531 \| Pain \| 2 HP:0003072 \| Hypercalcemia \| 2 HP:0001919 \| Acute renal failure \| 2 HP:0001903 \| Anemia \| 2 HP:0000083 \| Renal insufficiency \| 2 HP:0001909 \| Leukemia \| 2 HP:0002721 \| Immunodeficiency \| 2 HP:0012190 \| T cell lymphoma \| 2 HP:0003128 \| Lactic acidosis \| 2 HP:0001399 \| Liver failure \| 1 HP:0001369 \| Arthritis \| 1 HP:0000952 \| Yellow skin \| 1 HP:0012819 \| Myocarditis \| 1 HP:0030833 \| Neck pain \| 1 HP:0001009 \| Telangiectases \| 1 HP:0012050 \| Anasarca \| 1 HP:0000821 \| Underactive thyroid \| 1 HP:0002890 \| Thyroid carcinoma \| 1 HP:0001701 \| Pericarditis \| 1 HP:0001873 \| Low platelet count \| 1 HP:0040075 \| Hypopituitarism \| 1 HP:0002754 \| Bone infection \| 1 HP:0001973 \| Autoimmune thrombocytopenia \| 1 HP:0005523 \| Lymphoproliferative disorder \| 1 HP:0000846 \| Hypoadrenalism \| 1 HP:0001698 \| Pericardial effusions \| 1 HP:0006530 \| Interstitial lung disease \| 1 HP:0000716 \| Depression \| 1 HP:0100279 \| Ulcerative colitis \| 1 HP:0000819 \| Diabetes mellitus \| 1 HP:0002653 \| Bone pain \| 1 HP:0010628 \| Facial palsy, unilateral or bilateral \| 1 HP:0005214 \| Bowel obstruction \| 1 HP:0006515 \| Interstitial pneumonitis \| 1 HP:0002960 \| Autoimmune condition \| 1 HP:0030786 \| Photopsia \| 1 HP:0012539 \| Non-Hodgkin lymphoma \| 1 HP:0005547 \| Myeloproliferative disorder \| 1 HP:0002860 \| Squamous cell carcinoma \| 1 HP:0001251 \| Ataxia \| 1 HP:0002894 \| Neoplasia of the pancreas \| 1 HP:0011787 \| Central hypothyroidism \| 1 HP:0002633 \| Vasculitis \| 1 HP:0002608 \| Celiac disease \| 1 HP:0011034 \| Amyloid disease \| 1 HP:0001945 \| Fever \| 1 HP:0001513 \| Obesity \| 1 HP:0002725 \| Systemic lupus erythematosus \| 1 HP:0000618 \| Blindness \| 1 HP:0002893 \| Pituitary adenoma \| 1 HP:0001370 \| Rheumatoid arthritis \| 1 HP:0030766 \| Otalgia \| 1 HP:0002098 \| Respiratory distress \| 1 HP:0002277 \| Horner's syndrome \| 1 HP:0100723 \| Gastrointestinal stroma tumor \| 1 HP:0100008 \| Schwann cell tumour \| 1 HP:0002895 \| Papillary thyroid carcinoma \| 1 HP:0009792 \| Teratoma \| 1 HP:0001907 \| Thromboembolic disease \| 1 HP:0000790 \| Hematuria \| 1 HP:0006554 \| Acute hepatic failure \| 1 HP:0030731 \| Carcinoma \| 1

Disease ID	622
Disease	diffuse large b-cell lymphoma
Manually Symptom	UMLS \| Name(Total Manually Symptoms:11) C2364133 \| infection C1963091 \| diarrhea C1535939 \| pneumocystis jiroveci pneumonia C0877417 \| cytomegalovirus enterocolitis C0349412 \| refractory shock C0334634 \| mantle cell lymphoma C0040038 \| thromboembolism C0037140 \| b virus infection C0027697 \| nephritis C0018378 \| guillain-barre syndrome C0008626 \| chromosomal abnormality
Text Mined Symptom	UMLS \| Name \| Sentences' Count(Total Symptoms:4) C0009450 \| infection \| 5 C0037140 \| b virus infection \| 2 C0032305 \| pneumocystis jiroveci pneumonia \| 2 C0040038 \| thromboembolism \| 1

Manually Genotype(Total Text Mining Genotypes:0)
(Waiting for update.)

Text Mining Genotype(Total Genotypes:0)
(Waiting for update.)

All Snps(Total Genotypes:73)
snpId	pubmedId	geneId	geneSymbol	diseaseId	sourceId	sentence	score	Year	geneSymbol_dbSNP	CHROMOSOME	POS	REF	ALT
rs1045642	23829278	5243	ABCB1	umls:C0079744	BeFree	The present study evaluated the impact of single gene polymorphisms (SNPs: rs1801133 and rs1801131 in the MTHFR gene; rs4149056 and rs11045879 in the SLC01B1 gene; and rs2032582 and rs1045642 in the ABCB1 transporter gene) on MTX blood levels and toxicity in samples from 69 patients with diffuse large-B-cell lymphoma (DLBCL) treated with high dose intravenous (HD IV) MTX, > 2 g/m(2).	0.121628651	2014	ABCB1	7	87509329	A	T,G
rs1045642	23829278	4524	MTHFR	umls:C0079744	BeFree	The present study evaluated the impact of single gene polymorphisms (SNPs: rs1801133 and rs1801131 in the MTHFR gene; rs4149056 and rs11045879 in the SLC01B1 gene; and rs2032582 and rs1045642 in the ABCB1 transporter gene) on MTX blood levels and toxicity in samples from 69 patients with diffuse large-B-cell lymphoma (DLBCL) treated with high dose intravenous (HD IV) MTX, > 2 g/m(2).	0.013192369	2014	ABCB1	7	87509329	A	T,G
rs11045879	23829278	5243	ABCB1	umls:C0079744	BeFree	The present study evaluated the impact of single gene polymorphisms (SNPs: rs1801133 and rs1801131 in the MTHFR gene; rs4149056 and rs11045879 in the SLC01B1 gene; and rs2032582 and rs1045642 in the ABCB1 transporter gene) on MTX blood levels and toxicity in samples from 69 patients with diffuse large-B-cell lymphoma (DLBCL) treated with high dose intravenous (HD IV) MTX, > 2 g/m(2).	0.121628651	2014	SLCO1B1	12	21229685	T	C
rs11045879	23829278	4524	MTHFR	umls:C0079744	BeFree	The present study evaluated the impact of single gene polymorphisms (SNPs: rs1801133 and rs1801131 in the MTHFR gene; rs4149056 and rs11045879 in the SLC01B1 gene; and rs2032582 and rs1045642 in the ABCB1 transporter gene) on MTX blood levels and toxicity in samples from 69 patients with diffuse large-B-cell lymphoma (DLBCL) treated with high dose intravenous (HD IV) MTX, > 2 g/m(2).	0.013192369	2014	SLCO1B1	12	21229685	T	C
rs113488022	22575864	4893	NRAS	umls:C0079744	BeFree	Mutations of the BRAF gene were identified in six (24%) diffuse large B-cell lymphomas (D594G in three germinal center diffuse large B-cell lymphomas, K601N in two germinal center diffuse large B-cell lymphomas, and V600E in one non-germinal center diffuse large B-cell lymphoma) and of the NRAS gene in two (8%) non-germinal center diffuse large B-cell lymphomas (Q61K and Q61H).	0.000542884	2012	BRAF	7	140753336	A	T,G,C
rs113488022	22575864	673	BRAF	umls:C0079744	BeFree	Mutations of the BRAF gene were identified in six (24%) diffuse large B-cell lymphomas (D594G in three germinal center diffuse large B-cell lymphomas, K601N in two germinal center diffuse large B-cell lymphomas, and V600E in one non-germinal center diffuse large B-cell lymphoma) and of the NRAS gene in two (8%) non-germinal center diffuse large B-cell lymphomas (Q61K and Q61H).	0.000271442	2012	BRAF	7	140753336	A	T,G,C
rs11554290	9139869	4893	NRAS	umls:C0079744	BeFree	Altogether, one diffuse large B-cell lymphoma and one B-cell chronic lymphocytic leukemia (B-CLL) harbored a mutation (G12S and G12A, respectively) in the K-ras gene, and one B-CLL harbored a mutation (Q61R) in the N-ras gene.	0.000542884	1997	NRAS	1	114713908	T	G,C,A
rs121913237	9139869	4893	NRAS	umls:C0079744	BeFree	Altogether, one diffuse large B-cell lymphoma and one B-cell chronic lymphocytic leukemia (B-CLL) harbored a mutation (G12S and G12A, respectively) in the K-ras gene, and one B-CLL harbored a mutation (Q61R) in the N-ras gene.	0.000542884	1997	NRAS	1	114716126	C	T,G,A
rs121913250	9139869	4893	NRAS	umls:C0079744	BeFree	Altogether, one diffuse large B-cell lymphoma and one B-cell chronic lymphocytic leukemia (B-CLL) harbored a mutation (G12S and G12A, respectively) in the K-ras gene, and one B-CLL harbored a mutation (Q61R) in the N-ras gene.	0.000542884	1997	NRAS	1	114716127	C	T,G,A
rs121913254	22575864	673	BRAF	umls:C0079744	BeFree	Mutations of the BRAF gene were identified in six (24%) diffuse large B-cell lymphomas (D594G in three germinal center diffuse large B-cell lymphomas, K601N in two germinal center diffuse large B-cell lymphomas, and V600E in one non-germinal center diffuse large B-cell lymphoma) and of the NRAS gene in two (8%) non-germinal center diffuse large B-cell lymphomas (Q61K and Q61H).	0.000271442	2012	NRAS	1	114713909	G	T,C
rs121913254	22575864	4893	NRAS	umls:C0079744	BeFree	Mutations of the BRAF gene were identified in six (24%) diffuse large B-cell lymphomas (D594G in three germinal center diffuse large B-cell lymphomas, K601N in two germinal center diffuse large B-cell lymphomas, and V600E in one non-germinal center diffuse large B-cell lymphoma) and of the NRAS gene in two (8%) non-germinal center diffuse large B-cell lymphomas (Q61K and Q61H).	0.000542884	2012	NRAS	1	114713909	G	T,C
rs121913255	22575864	673	BRAF	umls:C0079744	BeFree	Mutations of the BRAF gene were identified in six (24%) diffuse large B-cell lymphomas (D594G in three germinal center diffuse large B-cell lymphomas, K601N in two germinal center diffuse large B-cell lymphomas, and V600E in one non-germinal center diffuse large B-cell lymphoma) and of the NRAS gene in two (8%) non-germinal center diffuse large B-cell lymphomas (Q61K and Q61H).	0.000271442	2012	NRAS	1	114713907	T	A
rs121913255	22575864	4893	NRAS	umls:C0079744	BeFree	Mutations of the BRAF gene were identified in six (24%) diffuse large B-cell lymphomas (D594G in three germinal center diffuse large B-cell lymphomas, K601N in two germinal center diffuse large B-cell lymphomas, and V600E in one non-germinal center diffuse large B-cell lymphoma) and of the NRAS gene in two (8%) non-germinal center diffuse large B-cell lymphomas (Q61K and Q61H).	0.000542884	2012	NRAS	1	114713907	T	A
rs121913338	22575864	4893	NRAS	umls:C0079744	BeFree	Mutations of the BRAF gene were identified in six (24%) diffuse large B-cell lymphomas (D594G in three germinal center diffuse large B-cell lymphomas, K601N in two germinal center diffuse large B-cell lymphomas, and V600E in one non-germinal center diffuse large B-cell lymphoma) and of the NRAS gene in two (8%) non-germinal center diffuse large B-cell lymphomas (Q61K and Q61H).	0.000542884	2012	BRAF	7	140753354	T	C,A
rs121913338	22575864	673	BRAF	umls:C0079744	BeFree	Mutations of the BRAF gene were identified in six (24%) diffuse large B-cell lymphomas (D594G in three germinal center diffuse large B-cell lymphomas, K601N in two germinal center diffuse large B-cell lymphomas, and V600E in one non-germinal center diffuse large B-cell lymphoma) and of the NRAS gene in two (8%) non-germinal center diffuse large B-cell lymphomas (Q61K and Q61H).	0.000271442	2012	BRAF	7	140753354	T	C,A
rs121913365	22575864	4893	NRAS	umls:C0079744	BeFree	Mutations of the BRAF gene were identified in six (24%) diffuse large B-cell lymphomas (D594G in three germinal center diffuse large B-cell lymphomas, K601N in two germinal center diffuse large B-cell lymphomas, and V600E in one non-germinal center diffuse large B-cell lymphoma) and of the NRAS gene in two (8%) non-germinal center diffuse large B-cell lymphomas (Q61K and Q61H).	0.000542884	2012	BRAF	7	140753332	T	G
rs121913365	22575864	673	BRAF	umls:C0079744	BeFree	Mutations of the BRAF gene were identified in six (24%) diffuse large B-cell lymphomas (D594G in three germinal center diffuse large B-cell lymphomas, K601N in two germinal center diffuse large B-cell lymphomas, and V600E in one non-germinal center diffuse large B-cell lymphoma) and of the NRAS gene in two (8%) non-germinal center diffuse large B-cell lymphomas (Q61K and Q61H).	0.000271442	2012	BRAF	7	140753332	T	G
rs12711521	23055202	4155	MBP	umls:C0079744	BeFree	A SNP-based analysis showed that MBP rs8094402 was associated with decreased risks of overall NHL (allele risk OR = 0.72, P-trend = 0.0018), DLBCL (allele risk OR = 0.72, P-trend = 0.036), and FL (allele risk OR = 0.67, P-trend = 0.021), while MASP2 rs12711521 was associated with a decreased risk of DLBCL (allele risk OR = 0.57, P-trend = 0.0042).	0.000271442	2013	MASP2	1	11030859	C	A
rs12711521	23055202	10747	MASP2	umls:C0079744	BeFree	A SNP-based analysis showed that MBP rs8094402 was associated with decreased risks of overall NHL (allele risk OR = 0.72, P-trend = 0.0018), DLBCL (allele risk OR = 0.72, P-trend = 0.036), and FL (allele risk OR = 0.67, P-trend = 0.021), while MASP2 rs12711521 was associated with a decreased risk of DLBCL (allele risk OR = 0.57, P-trend = 0.0042).	0.000271442	2013	MASP2	1	11030859	C	A
rs12917	22430443	4255	MGMT	umls:C0079744	BeFree	After stratification by major NHL histological subtypes, MGMT (rs12917) modified the association between chlorinated solvents and the risk of diffuse large B-cell lymphoma (Pfor interaction=0.0027) and follicular lymphoma (Pfor interaction=0.0024).	0.005081451	2012	MGMT	10	129708019	C	T
rs13181	23619945	2068	ERCC2	umls:C0079744	BeFree	A significant interaction with BMI was only observed for WRN (rs1801195; P = 0.004) for T-cell lymphoma and ERCC2 (rs13181; P = 0.002) for diffuse large B-cell lymphoma.	0.005819831	2013	ERCC2;KLC3	19	45351661	T	A,G
rs13181	23619945	7486	WRN	umls:C0079744	BeFree	A significant interaction with BMI was only observed for WRN (rs1801195; P = 0.004) for T-cell lymphoma and ERCC2 (rs13181; P = 0.002) for diffuse large B-cell lymphoma.	0.002909916	2013	ERCC2;KLC3	19	45351661	T	A,G
rs13255292	25261932	5820	PVT1	umls:C0079744	GWASCAT	Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma.	0.12	2014	PVT1	8	128064327	C	T
rs1625895	25430047	7157	TP53	umls:C0079744	BeFree	The G/G genotype of the TP53 rs1625895 polymorphism was shown to be associated with a high probability of R-CHOP therapy failure in DLBCL patients according to the probability of remission as well as 5-year overall and relapse-free survivals.	0.026612573	2014	TP53	17	7674797	T	G,C
rs1625895	25430047	1649	DDIT3	umls:C0079744	BeFree	The G/G genotype of the TP53 rs1625895 polymorphism was shown to be associated with a high probability of R-CHOP therapy failure in DLBCL patients according to the probability of remission as well as 5-year overall and relapse-free survivals.	0.014114977	2014	TP53	17	7674797	T	G,C
rs172378	21883784	712	C1QA	umls:C0079744	BeFree	The influence of C1qA-A276G polymorphisms in DLBCL, and the impact of both polymorphisms on susceptibility to LON and outcome were also examined.	0.002909916	2012	C1QA	1	22638945	A	G
rs1799782	17666372	7515	XRCC1	umls:C0079744	BeFree	In addition, the XRCC1 Arg194Trp polymorphism was associated with decreased NHL risk (Arg/Trp vs. Arg/Arg, OR: 0.72; 95% CI: 0.49-1.07; Trp/Trp vs. Arg/Arg, OR: 0.45; 95% CI: 0.10-1.99; p trend: 0.059), mainly in diffuse large B-cell lymphoma.	0.005276948	2007	XRCC1	19	43553422	G	A
rs1800629	23391141	7124	TNF	umls:C0079744	BeFree	Variants in TNFα (rs1800629) (GG vs. AG/AA, p < 0.001) and LTA (rs909253) (AA vs. AG/GG, p = 0.02) and deletions in GSTM1 and GSTT1 (undeleted vs. deleted, p = 0.01 and p = 0.01, respectively) were associated with increased susceptibility of developing DLBCL.	0.008262808	2014	TNF	6	31575254	G	A
rs1800629	23391141	2944	GSTM1	umls:C0079744	BeFree	Variants in TNFα (rs1800629) (GG vs. AG/AA, p < 0.001) and LTA (rs909253) (AA vs. AG/GG, p = 0.02) and deletions in GSTM1 and GSTT1 (undeleted vs. deleted, p = 0.01 and p = 0.01, respectively) were associated with increased susceptibility of developing DLBCL.	0.00554839	2014	TNF	6	31575254	G	A
rs1800629	23640160	7124	TNF	umls:C0079744	BeFree	TNF rs1800629, which was genotyped in only two of our studies, was also associated with B cell lymphoma (per-allele OR = 0.77, 95 % CI 0.64-0.91; p trend = 0.003), specifically DLBCL (per-allele OR = 0.69, 95 % CI 0.55-0.86; p trend = 0.001).	0.008262808	2013	TNF	6	31575254	G	A
rs1800629	23391141	2952	GSTT1	umls:C0079744	BeFree	Variants in TNFα (rs1800629) (GG vs. AG/AA, p < 0.001) and LTA (rs909253) (AA vs. AG/GG, p = 0.02) and deletions in GSTM1 and GSTT1 (undeleted vs. deleted, p = 0.01 and p = 0.01, respectively) were associated with increased susceptibility of developing DLBCL.	0.00554839	2014	TNF	6	31575254	G	A
rs1800890	20087644	3586	IL10	umls:C0079744	BeFree	IL10 rs1800890 was associated with risk of diffuse large B-cell lymphoma (OR 1.41, CI 1.08-1.85 for minor allele homozygosity) and mantle cell lymphoma (OR 1.77, CI 1.04-3.00).	0.01617823	2010	IL10	1	206776020	A	T
rs1800890	22609637	3586	IL10	umls:C0079744	BeFree	Compared with women who were never occupationally exposed to any organic solvents, women who were exposed to organic solvents at least once had a significantly increased risk for diffuse large B-cell lymphoma if they carried the IL10 (rs1800890) TT genotype (odds ratio=3.31, 95% confidence interval: 1.80-6.08), but not if they carried the AT/AA genotype (odds ratio=1.14, 95% confidence interval: 0.72-1.79).	0.01617823	2013	IL10	1	206776020	A	T
rs1800896	23640160	3586	IL10	umls:C0079744	BeFree	IL10 rs1800896 was associated with B cell lymphoma [per-allele odds ratio (OR) = 1.25, 95 % confidence interval (CI) 1.08-1.45; p trend = 0.003], specifically diffuse large B cell lymphoma (DLBCL) (per-allele OR = 1.29, 95 % CI 1.08-1.53; p trend = 0.004), as well as T cell lymphoma (per-allele OR = 1.44, 95 % CI 1.13-1.82; p trend = 0.003).	0.01617823	2013	IL10	1	206773552	T	C
rs1801131	23829278	4524	MTHFR	umls:C0079744	BeFree	The present study evaluated the impact of single gene polymorphisms (SNPs: rs1801133 and rs1801131 in the MTHFR gene; rs4149056 and rs11045879 in the SLC01B1 gene; and rs2032582 and rs1045642 in the ABCB1 transporter gene) on MTX blood levels and toxicity in samples from 69 patients with diffuse large-B-cell lymphoma (DLBCL) treated with high dose intravenous (HD IV) MTX, > 2 g/m(2).	0.013192369	2014	MTHFR	1	11794419	T	G
rs1801131	23829278	5243	ABCB1	umls:C0079744	BeFree	The present study evaluated the impact of single gene polymorphisms (SNPs: rs1801133 and rs1801131 in the MTHFR gene; rs4149056 and rs11045879 in the SLC01B1 gene; and rs2032582 and rs1045642 in the ABCB1 transporter gene) on MTX blood levels and toxicity in samples from 69 patients with diffuse large-B-cell lymphoma (DLBCL) treated with high dose intravenous (HD IV) MTX, > 2 g/m(2).	0.121628651	2014	MTHFR	1	11794419	T	G
rs1801133	23829278	5243	ABCB1	umls:C0079744	BeFree	The present study evaluated the impact of single gene polymorphisms (SNPs: rs1801133 and rs1801131 in the MTHFR gene; rs4149056 and rs11045879 in the SLC01B1 gene; and rs2032582 and rs1045642 in the ABCB1 transporter gene) on MTX blood levels and toxicity in samples from 69 patients with diffuse large-B-cell lymphoma (DLBCL) treated with high dose intravenous (HD IV) MTX, > 2 g/m(2).	0.121628651	2014	MTHFR	1	11796321	G	A
rs1801133	23829278	4524	MTHFR	umls:C0079744	BeFree	The present study evaluated the impact of single gene polymorphisms (SNPs: rs1801133 and rs1801131 in the MTHFR gene; rs4149056 and rs11045879 in the SLC01B1 gene; and rs2032582 and rs1045642 in the ABCB1 transporter gene) on MTX blood levels and toxicity in samples from 69 patients with diffuse large-B-cell lymphoma (DLBCL) treated with high dose intravenous (HD IV) MTX, > 2 g/m(2).	0.013192369	2014	MTHFR	1	11796321	G	A
rs1801195	23619945	2068	ERCC2	umls:C0079744	BeFree	A significant interaction with BMI was only observed for WRN (rs1801195; P = 0.004) for T-cell lymphoma and ERCC2 (rs13181; P = 0.002) for diffuse large B-cell lymphoma.	0.005819831	2013	WRN	8	31141764	G	T
rs1801195	23619945	7486	WRN	umls:C0079744	BeFree	A significant interaction with BMI was only observed for WRN (rs1801195; P = 0.004) for T-cell lymphoma and ERCC2 (rs13181; P = 0.002) for diffuse large B-cell lymphoma.	0.002909916	2013	WRN	8	31141764	G	T
rs1805010	19515749	3566	IL4R	umls:C0079744	GAD	[Favorable impact of the interleukin-4 receptor allelic variant I75 on the survival of diffuse large B-cell lymphoma patients demonstrated in a large prospective clinical trial.]	0.005005506	2009	IL4R	16	27344882	A	C,G,T
rs1880030	19336552	605	BCL7A	umls:C0079744	BeFree	Variants in BCL7A were strongly related to diffuse large B-cell lymphoma only, particularly rs1880030 (OR(AG), 1.34; 95% CI, 1.08-1.68; OR(AA), 1.60; 95% CI, 1.22-2.08; P(trend) = 0.0004).	0.002638474	2009	BCL7A	12	122046634	G	A
rs2032582	23829278	4524	MTHFR	umls:C0079744	BeFree	The present study evaluated the impact of single gene polymorphisms (SNPs: rs1801133 and rs1801131 in the MTHFR gene; rs4149056 and rs11045879 in the SLC01B1 gene; and rs2032582 and rs1045642 in the ABCB1 transporter gene) on MTX blood levels and toxicity in samples from 69 patients with diffuse large-B-cell lymphoma (DLBCL) treated with high dose intravenous (HD IV) MTX, > 2 g/m(2).	0.013192369	2014	ABCB1	7	87531302	A	T,C
rs2032582	23829278	5243	ABCB1	umls:C0079744	BeFree	The present study evaluated the impact of single gene polymorphisms (SNPs: rs1801133 and rs1801131 in the MTHFR gene; rs4149056 and rs11045879 in the SLC01B1 gene; and rs2032582 and rs1045642 in the ABCB1 transporter gene) on MTX blood levels and toxicity in samples from 69 patients with diffuse large-B-cell lymphoma (DLBCL) treated with high dose intravenous (HD IV) MTX, > 2 g/m(2).	0.121628651	2014	ABCB1	7	87531302	A	T,C
rs2231142	19032367	9429	ABCG2	umls:C0079744	BeFree	ABCG2 Q141K polymorphism is associated with chemotherapy-induced diarrhea in patients with diffuse large B-cell lymphoma who received frontline rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone chemotherapy.	0.123452799	2008	ABCG2	4	88131171	G	T
rs2234922	21228414	2052	EPHX1	umls:C0079744	BeFree	The weak, nonsignificant overall association between benzene and diffuse large B-cell lymphoma (OR = 1.29, 95% CI: 0.84, 1.98) was increased among women AA for rs2234922 in the microsomal epoxide hydrolase gene, EPHX1 (OR = 1.77, 95% CI: 1.06, 2.97; P(interaction) = 0.06).	0.000271442	2011	EPHX1	1	225838705	A	G,T
rs2523607	25261932	102465537	MIR6891	umls:C0079744	GWASCAT	Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma.	0.12	2014	HLA-B;MIR6891	6	31355013	T	A
rs2523607	25261932	3106	HLA-B	umls:C0079744	GWASCAT	Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma.	0.12	2014	HLA-B;MIR6891	6	31355013	T	A
rs2681416	25261932	942	CD86	umls:C0079744	GWASCAT	Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma.	0.12	2014	CD86	3	122098766	G	A
rs2910164	25370733	406938	MIR146A	umls:C0079744	BeFree	MicroRNA-146a rs2910164 polymorphism and the risk of diffuse large B cell lymphoma in the Chinese Han population.	0.000271442	2014	LOC285628;MIR146A	5	160485411	C	G
rs3813729	22170086	51279	C1RL	umls:C0079744	BeFree	A SNP-based analysis showed that a C>T base substitution for C1RL rs3813729 (odds ratio (OR)(CT) = 0.60, 95% confidence interval (CI) = 0.42-0.87, P(trend) = 0.0062) was associated with a decreased risk of overall NHL, as well as for DLBCL (OR(CT) = 0.39, 95% CI = 0.20-0.73; P(trend) = 0.0034).	0.000271442	2012	NA	NA	NA	NA	NA
rs386545546	17666372	7515	XRCC1	umls:C0079744	BeFree	In addition, the XRCC1 Arg194Trp polymorphism was associated with decreased NHL risk (Arg/Trp vs. Arg/Arg, OR: 0.72; 95% CI: 0.49-1.07; Trp/Trp vs. Arg/Arg, OR: 0.45; 95% CI: 0.10-1.99; p trend: 0.059), mainly in diffuse large B-cell lymphoma.	0.005276948	2007	NA	NA	NA	NA	NA
rs387907272	25768255	4615	MYD88	umls:C0079744	BeFree	Myd-88 L265P constitutive activating mutations are present in at least some cases of the diffuse large B-cell lymphoma form of vitreoretinal lymphoma.	0.122171535	2015	MYD88	3	38141150	T	C
rs387907272	23178471	4615	MYD88	umls:C0079744	BeFree	Heterozygous MYD88 L265P mutations were identified in 11 (9.2%) DLBCL cases, all of which were diagnosed as non-germinal-center B cell (non-GCB) DLBCL.	0.122171535	2013	MYD88	3	38141150	T	C
rs387907272	23380077	4615	MYD88	umls:C0079744	BeFree	MYD88 expression and L265P mutation in diffuse large B-cell lymphoma.	0.122171535	2013	MYD88	3	38141150	T	C
rs3957357	19448608	1535	CYBA	umls:C0079744	BeFree	Overall, host SNPs affecting doxorubicin pharmacodynamics (CYBA rs4673) and alkylator detoxification (GSTA1 rs3957357) may predict outcome in R-CHOP21-treated DLBCL.	0.000271442	2009	GSTA1	6	52803889	A	G
rs3957357	19448608	2938	GSTA1	umls:C0079744	BeFree	Overall, host SNPs affecting doxorubicin pharmacodynamics (CYBA rs4673) and alkylator detoxification (GSTA1 rs3957357) may predict outcome in R-CHOP21-treated DLBCL.	0.000271442	2009	GSTA1	6	52803889	A	G
rs4149056	23829278	5243	ABCB1	umls:C0079744	BeFree	The present study evaluated the impact of single gene polymorphisms (SNPs: rs1801133 and rs1801131 in the MTHFR gene; rs4149056 and rs11045879 in the SLC01B1 gene; and rs2032582 and rs1045642 in the ABCB1 transporter gene) on MTX blood levels and toxicity in samples from 69 patients with diffuse large-B-cell lymphoma (DLBCL) treated with high dose intravenous (HD IV) MTX, > 2 g/m(2).	0.121628651	2014	SLCO1B1	12	21178615	T	C
rs4149056	23829278	4524	MTHFR	umls:C0079744	BeFree	The present study evaluated the impact of single gene polymorphisms (SNPs: rs1801133 and rs1801131 in the MTHFR gene; rs4149056 and rs11045879 in the SLC01B1 gene; and rs2032582 and rs1045642 in the ABCB1 transporter gene) on MTX blood levels and toxicity in samples from 69 patients with diffuse large-B-cell lymphoma (DLBCL) treated with high dose intravenous (HD IV) MTX, > 2 g/m(2).	0.013192369	2014	SLCO1B1	12	21178615	T	C
rs4673	19448608	2938	GSTA1	umls:C0079744	BeFree	Overall, host SNPs affecting doxorubicin pharmacodynamics (CYBA rs4673) and alkylator detoxification (GSTA1 rs3957357) may predict outcome in R-CHOP21-treated DLBCL.	0.000271442	2009	CYBA	16	88646828	A	G
rs4673	19448608	1535	CYBA	umls:C0079744	BeFree	Overall, host SNPs affecting doxorubicin pharmacodynamics (CYBA rs4673) and alkylator detoxification (GSTA1 rs3957357) may predict outcome in R-CHOP21-treated DLBCL.	0.000271442	2009	CYBA	16	88646828	A	G
rs601341	17169801	4361	MRE11A	umls:C0079744	BeFree	A protective effect against follicular lymphoma was seen for the MRE11 rs601341 variant, the homozygous T allele being associated with an odds ratio (OR) of 0.50, 95% confidence interval (95% CI) 0.26 - 0.97, while a protective effect was seen for the MRE11 haplotype GCTCA (OR 0.72, 95% CI 0.53 - 0.97) for diffuse large B-cell lymphoma.	0.000271442	2006	MRE11A	11	94434611	G	A
rs6773854	23749188	51750	RTEL1	umls:C0079744	BeFree	We identified a new susceptibility locus, rs6773854, located between BCL6 (encoding B cell lymphoma protein 6) and LPP (encoding lipoma preferred partner) on oncogene-rich chromosome 3q27 that was significantly associated with increased risk of B cell NHL (meta-analysis P = 3.36 × 10⁻¹³, per-allele odds ratio (OR) = 1.44) and with diffuse large B cell lymphoma (DLBCL) in particular (meta-analysis P = 1.14 × 10⁻¹¹, OR = 1.47).	0.003257302	2013	LOC105374265	3	187931631	T	C
rs6773854	23749188	4026	LPP	umls:C0079744	BeFree	We identified a new susceptibility locus, rs6773854, located between BCL6 (encoding B cell lymphoma protein 6) and LPP (encoding lipoma preferred partner) on oncogene-rich chromosome 3q27 that was significantly associated with increased risk of B cell NHL (meta-analysis P = 3.36 × 10⁻¹³, per-allele odds ratio (OR) = 1.44) and with diffuse large B cell lymphoma (DLBCL) in particular (meta-analysis P = 1.14 × 10⁻¹¹, OR = 1.47).	0.000271442	2013	LOC105374265	3	187931631	T	C
rs6773854	23749188	604	BCL6	umls:C0079744	BeFree	We identified a new susceptibility locus, rs6773854, located between BCL6 (encoding B cell lymphoma protein 6) and LPP (encoding lipoma preferred partner) on oncogene-rich chromosome 3q27 that was significantly associated with increased risk of B cell NHL (meta-analysis P = 3.36 × 10⁻¹³, per-allele odds ratio (OR) = 1.44) and with diffuse large B cell lymphoma (DLBCL) in particular (meta-analysis P = 1.14 × 10⁻¹¹, OR = 1.47).	0.033311405	2013	LOC105374265	3	187931631	T	C
rs7097	21471979	51082	POLR1D	umls:C0079744	GAD	[Common variants on 14q32 and 13q12 are associated with DLBCL susceptibility.]	0.002367032	2011	POLR1D	13	27623299	C	T
rs751837	21471979	9578	CDC42BPB	umls:C0079744	GAD	[Common variants on 14q32 and 13q12 are associated with DLBCL susceptibility.]	0.002367032	2011	CDC42BPB	14	103018488	T	C
rs79464052	25261932	64411	ARAP3	umls:C0079744	GWASCAT	Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma.	0.12	2014	ARAP3	5	141655607	G	C
rs8094402	23055202	4155	MBP	umls:C0079744	BeFree	A SNP-based analysis showed that MBP rs8094402 was associated with decreased risks of overall NHL (allele risk OR = 0.72, P-trend = 0.0018), DLBCL (allele risk OR = 0.72, P-trend = 0.036), and FL (allele risk OR = 0.67, P-trend = 0.021), while MASP2 rs12711521 was associated with a decreased risk of DLBCL (allele risk OR = 0.57, P-trend = 0.0042).	0.000271442	2013	MBP	18	76995493	A	G
rs8094402	23055202	10747	MASP2	umls:C0079744	BeFree	A SNP-based analysis showed that MBP rs8094402 was associated with decreased risks of overall NHL (allele risk OR = 0.72, P-trend = 0.0018), DLBCL (allele risk OR = 0.72, P-trend = 0.036), and FL (allele risk OR = 0.67, P-trend = 0.021), while MASP2 rs12711521 was associated with a decreased risk of DLBCL (allele risk OR = 0.57, P-trend = 0.0042).	0.000271442	2013	MBP	18	76995493	A	G
rs909253	23391141	7124	TNF	umls:C0079744	BeFree	Variants in TNFα (rs1800629) (GG vs. AG/AA, p < 0.001) and LTA (rs909253) (AA vs. AG/GG, p = 0.02) and deletions in GSTM1 and GSTT1 (undeleted vs. deleted, p = 0.01 and p = 0.01, respectively) were associated with increased susceptibility of developing DLBCL.	0.008262808	2014	LTA;LOC100287329	6	31572536	A	G
rs909253	23391141	2952	GSTT1	umls:C0079744	BeFree	Variants in TNFα (rs1800629) (GG vs. AG/AA, p < 0.001) and LTA (rs909253) (AA vs. AG/GG, p = 0.02) and deletions in GSTM1 and GSTT1 (undeleted vs. deleted, p = 0.01 and p = 0.01, respectively) were associated with increased susceptibility of developing DLBCL.	0.00554839	2014	LTA;LOC100287329	6	31572536	A	G
rs909253	23391141	2944	GSTM1	umls:C0079744	BeFree	Variants in TNFα (rs1800629) (GG vs. AG/AA, p < 0.001) and LTA (rs909253) (AA vs. AG/GG, p = 0.02) and deletions in GSTM1 and GSTT1 (undeleted vs. deleted, p = 0.01 and p = 0.01, respectively) were associated with increased susceptibility of developing DLBCL.	0.00554839	2014	LTA;LOC100287329	6	31572536	A	G

GWASdb Annotation(Total Genotypes:0)
(Waiting for update.)

GWASdb Snp Trait(Total Genotypes:0)
(Waiting for update.)

Mapped by lexical matching(Total Items:0)
(Waiting for update.)

Mapped by homologous gene(Total Items:0)
(Waiting for update.)

Disease ID	622
Disease	diffuse large b-cell lymphoma
Case	(Waiting for update.)